New breath test accurately detects cannabinoids in recent use

Researchers have developed and validated a standardized method for detecting cannabinoids in exhaled breath, specifically measuring Δ9-THC, Δ8-THC, CBD, and CBN. Using the Cannabix Technologies Breath Collection Unit, this analytical approach provides quantitatively reproducible results with high chromatographic resolution and selectivity across over 400 authentic breath samples. The method successfully differentiates between Δ8-THC and Δ9-THC, addressing a critical challenge in breath-based cannabinoid testing.

Breath is an attractive non-invasive matrix for cannabis testing because it has a short detection window for Δ9-THC, making it particularly useful for assessing recent cannabis use rather than accumulated long-term use. The validation followed established forensic standards, meeting accepted analytical criteria (Rs = 0.9) as recommended by NLCP guidelines for workplace drug testing. This creates a robust analytical platform that could support regulatory frameworks and scientific research.

Importantly, this method is designed to provide an objective analytical framework for quantifying cannabinoids rather than directly measure impairment. As cannabis becomes increasingly regulated across jurisdictions, having a standardized, reproducible breath test provides a foundation for future pharmacokinetic and pharmacodynamic studies. The development of reliable breath-based detection tools may help establish evidence-based standards for cannabis use monitoring in occupational and legal contexts.